ReviewBlood cancer journal2022

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.

Oliver Van Oekelen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.